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Results: Compared with essential hypertensive patients, those with hyper-
aldosteronism were younger (56.9 [11.7] years vs 60 [14.4] years; P<.001),
had higher blood pressure prior to the etiological diagnosis (156 [23.2] mmHg
vs 136 [20.6] mmHg), more frequently had a family history of early cardio-
vascular disease (26.7% vs 2.3%; P<.001), and had a higher prevalence of
concentric left ventricular hypertrophy (72% vs 25.4%) and higher cardiovas-
cular risk. Specific treatment resulted in optimal control of systolic and dia-
stolic blood pressures (from 150.7 [23.0] mmHg and 86.15 [14.07] mmHg to
12.69 [15.3] mmHg and 76.34 [9.7] mmHg, respectively). We suspected the
presence of hyperaldosteronism because of resistant hypertension (38.6%),
hypokalemia (39.7%), and hypertensive crises (12.7%). Only 4.3% of these
patients had been referred from primary care with a suspected diagnosis of
hyperaldosteronism.
Conclusions: Hyperaldosteronism should be suspected in cases of resistant
hypertension, hypokalemia and hypertensive crises. The diagnosis of hyperal-
dosteronism allows better blood pressure control. The most prevalent target
organ damage is left ventricular hypertrophy.
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Despite a well-recognized clinical benefit of the 2nd generation tyrosine
kinase inhibitor nilotinib in patients with imatinib-resistant/-intolerant or
newly diagnosed chronic myeloid leukemia, recent evidence suggests that
nilotinib has a propensity to increase the risk of occlusive arterial events, espe-
cially in patients with pre-existing cardiovascular risk factors. Given the key
role of lipids in cardiovascular diseases, we studied the plasma lipid profile
and global cardiovascular risk prior to and during nilotinib therapy in a series
of 27 patients in the setting of an observationalsingle-center study. Data from
a minimum 1-year follow-up showed that nilotinib significantly increased
total, low and highdensity lipoprotein cholesterol within 3 months. Conse-
quently, the proportion of patients with non-optimal low density lipoprotein
cholesterol increased from 48.1% to 88.9% by 12 months, leading to choles-
terol-lowering drug intervention in 22.2% of patients. The proportion of
patients with low levels of high density lipoprotein cholesterol decreased from
40.7% to 7.4% by 12 months. In contrast, a significant decrease in triglycer-
ides was observed. Global cardiovascular risk worsened in 11.1% of patients
due to diabetes or occlusive arterial events. Whether hypercholesterolemia
was the main driver of occlusive arterial events was uncertain: a longer
follow-up is necessary to ask whether nilotinib-induced hypercholesterolemia
increaseslong-term risk of atherosclerotic diseases. Nevertheless, given
keyatherogenicproperties of low density lipoprotein cholesterol, we conclude
that when prescribing nilotinib, commitment to detect lipid disordersat base-
line and during follow-up is mandatory given their frequency, requirement
for lifestyle or drug intervention and potential for long-term cardiovascular
complications. 
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Background: Nilotinib is approved for use in pts with CML after failure
of imatinib and in newly diagnosed CP-CML. However, several studies
report a nilotinib-associated risk of AOE (arterial occlusive event), espe-
cially in pts with preexisting risk factors for CVD. In this study, we aimed
at determining whether CVD risk estimation using the 2012 ESC classifica-
tion could be useful to identify patients at high risk of AOE during nilotinib
therapy.
Methods: Pts (n=75) treated with nilotinib upfront or after failure of prior
TKI at our institution were included provided that baseline CVD status could
be retrospectively collected. Patients were categorized into 2 groups according
to ESC 2012 classification: low/moderate (L/M) and high/very high (H/VH)
CVD risk.
Results: At nilotinib initiation, median age was 51 years (19-76), 41 pts
(54.7%) were males. At baseline, medical history revealed H/VH risk category
in 15 pts (20%) including established CVD in 6 pts (8%) (all diagnosed before
CML), DM (diabete melitus) in 10 pts (13.3%), severe AH (arterial hyperten-
sion) in 1 pt (1.3%), familial dyslipidemia in 1 pt (1.3%) and a SCORE ≥5%
in 2 pts (2.6%). 
AOE occurred in 12 pts with myocardial infarction (MI) or coronary heart
disease (CHD) (n=3), cerebrovascular events (CeVD) (n=3) and peripheral
artery disease (PAD) (n=6). Cumulative incidence of AOE by 48 months was
72.22% (95% CI: 47.46-100) in the H/VH group and only 12.13% (95% CI:
4.32-34.08) in the L/M group. Log Rank comparison of Kaplan Meier analysis
of 48-month survival without AOE showed a significant difference between
the 2 groups (27.78% (95% CI: 0-58.9) versus 84.38% (95% CI: 67.04-100)
p=0.0001). Sensitivity of the ESC classification in nilotinib-treated patients
was 67% and specificity 89%. 
Conclusions: In our retrospective study, CVD risk estimation
according to the 2012 ESC classification reveals that pts who belong to the
H/VH risk group at baseline are at very high risk of AOE during nilotinib
therapy. In this context, CVD risk should be reassessed throughout therapy
and risk factors should be tightly controlled according to current guide-
lines. 
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Background: While venous manifestations are frequent and have been
reported in many publications, data regarding arterial lesions in patients with
Behçet's disease (BD) are rare and often isolated.
Aim: We report our experience with a rare and interesting subset of BD
patients with arterial involvement
Methods: From 1998 to 2013, 20 cases of arterial involvement were found
amongst BD patients in the department of internal medicine of Hedi Chaker
Hospital. All these patients fulfilled International Study Group criteria for BD.
Results: The mean age when arterial involvement manifested was diag-
nosed was 32.9±9.9 years, and 18 of the patients were male. Combination of
venous and arterial manifestations occurred in 10 patients The artery most
often affected is the pulmonary arteries (11 cases) followed by the aorta, the
femoral arteries (5 cases) and the coronary arteries (4 cases). The arterial
disease was the presenting symptom of Behcet's disease in 13 cases. Arterial
lesions included arterial thromboses (45%), aneurysms (30%), stenosis
(20%) and Coronaritis (5%). 15 patients underwent corticosteroids and
4 patients underwent immunosuppressive therapy. Three patients were suc-
cessfully operated for aneurysms. After a median follow-up of 66.9± 54.4
months, 3 patients had died, in 2 cases directly related to cardiac involve-
ment.
Conclusion: Arterial findings are not uncommon in BD. Assessment of the
cardiovascular system is advised in patients with BD even if there is no cli-
nically apparent cardiovascular disease. 
